Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks. J of Skin [Internet]. 2024 Mar. 18 [cited 2025 Apr. 18];8(2):s377. Available from: https://skin.dermsquared.com/skin/article/view/2680